LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Roivant Sciences Ltd

Closed

SectorHealthcare

11.22 0.27

Overview

Share price change

24h

Current

Min

11.11

Max

11.24

Key metrics

By Trading Economics

Income

212M

25M

Sales

4.5M

9M

EPS

-0.218

Profit margin

280.018

Employees

750

EBITDA

-52M

-274M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+42.86% upside

Market Stats

By TradingEconomics

Market Cap

7.6B

Previous open

10.95

Previous close

11.22

News Sentiment

By Acuity

50%

50%

166 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 cze 2025, 14:31 UTC

Earnings

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 cze 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 cze 2025, 20:33 UTC

Earnings

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 cze 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 cze 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 cze 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 cze 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 cze 2025, 16:35 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 cze 2025, 16:34 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 cze 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 cze 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 cze 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 cze 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 cze 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 cze 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 cze 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 cze 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 cze 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 cze 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 cze 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 cze 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 cze 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 cze 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 cze 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 cze 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 cze 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 cze 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 cze 2025, 14:12 UTC

Earnings

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 cze 2025, 14:09 UTC

Earnings

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

42.86% upside

12 Months Forecast

Average 16 USD  42.86%

High 18 USD

Low 12 USD

Based on 7 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

166 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.